A Study to Evaluate the Safety and Effectiveness of JUVÉDERM Products in Adult Participants for the Change of Their Overall Facial Appearance
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 4
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
75actual
Sites
10
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-25 | actual | When the study began enrolling |
| Primary completion | 2026-07-08 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-08 | actual | The whole study's end, after follow-up |
| First posted | 2025-09-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Mid Face Volume Deficit
Interventions
- Device: JUVÉDERM VOLUX XC
- Device: JUVÉDERM VOLUMA XC
- Device: JUVÉDERM VOLBELLA XC
- Device: JUVÉDERM VOLLURE XC
- Device: SKINVIVE by JUVÉDERM
- Device: JUVÉDERM ULTRA XC
- Device: JUVÉDERM ULTRA PLUS XC
Primary outcomes
what the primary-completion date above is the date OFChange from Baseline in the Participant's Rasch-Transformed Score of the FACE-Q™ Satisfaction with Facial Appearance Scale
measured Month 3
Number of Participants with Adverse Events (AEs)
measured Up to approximately Month 6
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed